Loading
Life sciences · Journal article
Genes · October 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Transforming growth factor-β (TGF-β) signalling plays a complex and context-dependent role in prostate cancer, functioning as a tumour suppressor in early disease while promoting epithelial plasticity, immune evasion, metastatic progression, and treatment resistance in advanced tumours. We conducted a structured literature review to examine the biological, clinical, and translational significance of TGF-β pathway dysregulation in prostate cancer, with a particular focus on biomarker development, therapeutic opportunities, and barriers to clinical implementation. Evidence from human studies suggests that altered TGF-β expression, circulating biomarkers, and pathway-associated genetic variation are associated with aggressive disease features, biochemical recurrence, metastasis, and adverse clinical outcomes. However, translation into clinically useful biomarkers has been hindered by substantial heterogeneity in analytes, assay methodologies, patient populations, and outcome measures. Mechanistic and preclinical studies further demonstrate that TGF-β signalling contributes to epithelial–mesenchymal transition, tumour microenvironment remodelling, immune suppression, and resistance to androgen-receptor-directed therapies, chemotherapy, and radiotherapy. These findings have stimulated the development of TGF-β-targeted therapeutic strategies, particularly in combination with immunotherapies, DNA-damage-response-targeted agents, and established systemic treatments. Nevertheless, the pleiotropic and stage-specific functions of TGF-β, together with concerns regarding toxicity and patient selection, present significant challenges to therapeutic intervention. Future progress will depend on the development of robust and standardised biomarkers, prospective validation in clinically relevant cohorts, and trial designs that incorporate pathway activity, tumour microenvironmental context, and disease stage into treatment selection. Collectively, current evidence positions TGF-β signalling as a promising but biologically complex target for advancing precision medicine in prostate cancer.